



## Pancreatic Ductal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches

Guest Editor:

**Dr. Rossano Lattanzio**

Center for Advanced Studies and Technology (CAST), Department of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio" Chieti-Pescara, 66100 Chieti, Italy

Deadline for manuscript submissions:

**closed (31 January 2021)**

### Message from the Guest Editor

Dear Colleagues,

Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. The dismal prognosis of PC patients is attributable to the strong propensity of the disease to disseminate at an early stage. Thus, at the time of diagnosis, only 20% of PC patients are eligible for surgical resection. Furthermore, resistance to chemotherapy and radiotherapy contributes to the high mortality rates registered in PC patients. This Special Issue will provide insights regarding the molecular pathogenesis of PC and how the molecular driver of PC cells could be targeted. Authors are invited to submit their original research, communications, and review articles to Biomedicines. Potential topics include but not limited to:

- The role of cancer stem cells or tumor-initiating cells in the genesis and progression of PC;
- Genetic changes and gene expression patterns associated with PC subtypes;
- The impact of the epigenetic changes in PC;
- The contribution of tumor stroma in the PC;
- Potential biomarkers for predicting the progression and response to therapy of PC;
- The immuno-oncology approaches in PC;
- Antistroma therapies in PC;
- Role of the exosomes in PC.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)